AstraZeneca said results from clinical trials showed that a drug to treat patients with anaemia from chronic kidney disease had significantly increased red haemoglobin levels. The so-called Olympus trial compared AstraZeneca's roxadustat to placebo while the Rockies trial compared the drug to epoetin alfa. 'Anaemia is a common, serious condition among patients with chronic kidney disease,' said Mene Pangalos, executive vice president, BioPharmaceuticals R&D. 'It occurs when the body has fewer healthy red blood cells than normal and low levels of haemoglobin, which may leave patients fatigued and short of breath.' 'Results from olympus and rockies reinforce the potential role that roxadustat could play in increasing haemoglobin levels and managing anaemia, which is often underdiagnosed and undertreated.'
-52.00p (-0.70%)delayed 14:17PM